Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
A group of 20 patients who met the DSM-III-R criteria for panic disorder with or without agoraphobia underwent a 35% carbon dioxide (CO2) challenge after either 1 mg alprazolam or placebo in a double-blind, randomized, cross-over design. Despite the anxiolytic potential of alprazolam, it produced no significant effects on CO2-induced anxiety and panic symptomatology when compared to placebo.
Pols
H
H
Department of Psychiatry & Neuropsychology, State University of Limburg, Maastricht, The Netherlands.
Verburg
K
K
Hauzer
R
R
Meijer
J
J
Griez
E
E
D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D000525:Alprazolam / Q000008:administration & dosage*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D001143:Arousal / Q000187:drug effects; D002245:Carbon Dioxide; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010200:Panic / Q000187:drug effects; D016584:Panic Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D011292:Premedication; D011569:Psychiatric Status Rating Scales
D014151:Anti-Anxiety Agents; D002245:Carbon Dioxide; D000525:Alprazolam